oral tirzepatide development status Tirzepatide: First Approval | Drugs NEW: This new oral GLP-1
Description
The Bottom Line May 2026 Status Editorial note: This article is a news update covering FDA regulatory action as of May 2026
I wish you keep growing and keep shining Great Good
Plans frequently: exclude certain drugs, asking patients to use their preferred alternatives instead place them in high cost-sharing tiers, or cover them only for one use (e.g., diabetes) but not another (e.g., obesity)
Salimah Jones
Visit NexLife (Editor's #1 Pick)
It is possible that this trend is due, at least in part, to the off-label use of diabetes-approved GLP-1 RAs for weight loss in patients without diabetes
